Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $9.64, but opened at $9.98. Gyre Therapeutics shares last traded at $9.79, with a volume of 25,129 shares.
Gyre Therapeutics Stock Performance
The company has a 50-day simple moving average of $13.07 and a 200-day simple moving average of $12.61.
Institutional Investors Weigh In On Gyre Therapeutics
Several hedge funds have recently modified their holdings of the company. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter valued at approximately $47,000. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company's stock valued at $116,000 after purchasing an additional 6,855 shares during the last quarter. State Street Corp lifted its holdings in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Rhumbline Advisers acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at approximately $123,000. Finally, Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the second quarter worth approximately $166,000. 23.99% of the stock is owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
